ALK POSITIVE
Cart 0
Home ALKtALK Shop
Join
Research Grants Cutting Edge Trials Clinical Trials ALK Life Study
Get Support ALK+ Summit 2025 What is ALK Treatment & Resources 2nd Opinion Program
About Us Finances Alliances Contact Press
Blog Newsletters Prospectus Annual Report
Donate Ways to Give Fundraise with ALK+
Cart 0
Home Research Research Grants Cutting Edge Trials Clinical Trials ALK Life Study Patients Get Support ALK+ Summit 2025 What is ALK Treatment & Resources 2nd Opinion Program About About Us Finances Alliances Contact Press ALKtALK Media Blog Newsletters Prospectus Annual Report Shop
ALK POSITIVE
Donate Donate Ways to Give Fundraise with ALK+ Join

Kirk SmithDecember 26, 2021Comment
Facebook0 Twitter LinkedIn0 0 Likes
Previous

Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion

Case Study, group1Kirk SmithDecember 28, 2021alectinib, osimertinib, brain metastasis, ALK, lung, EGFR, DCTN1-ALK
Next

CD30-Directed Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Hodgkin Lymphoma and Non-Hodgkin Lymphoma in Pediatric Patients

Clinical Trials, group1Kirk SmithDecember 24, 2021Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma (HL), CD30.CAR-T cells, Anaplastic Large Cell Lymphoma (ALCL)
Donate
Join Support Group

info@alkpositive.org

ALK Positive, Inc. 6595 Roswell Road;

Suite G2310 Atlanta, GA 30328

Please send checks to:

ALK LOCKBOX, P.O. Box 24960 New York, New York 10087-4960

Subscribe

Sign up with your email address to receive news and updates.

We respect your privacy.

Thank you!
info@alkpositive.org
Hours
Mon Open
Tue Open
Wed Open
Thu Open
Fri Open
Sat Open
Sun Open
Log InPressHomeLinksContact UsBlogPrivacy Policy

The content on the ALK Positive website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.  © ALK Positive, Inc. All Rights Reserved